"25622"^^ . . . . . . . . . . . . . . . . . "1"^^ . "Shrnut\u00ED v\u00FDsledk\u016F dal\u0161\u00EDch farmakokinetick\u00FDch hodnocen\u00ED l\u00E9kov\u00FDch interakc\u00ED\n\tSou\u010Dasn\u011B pod\u00E1van\u00E9 l\u00E9\u010Divo \n\tKoncentrace sou\u010Dasn\u011B pod\u00E1van\u00E9ho l\u00E9\u010Divaa \n\tKoncentrace topiram\u00E1tua \n\tAmitriptylin \n\t\u219420% zv\u00FD\u0161en\u00ED Cmax a AUC metabolitu nortryptylinu \n\tNS \n\tDihydroergotamin (peror\u00E1ln\u00ED a subkut\u00E1nn\u00ED) \n\t\u2194 \n\t\u2194 \n\tHaloperidol \n\t\u219431% zv\u00FD\u0161en\u00ED AUC redukovan\u00E9ho metabolitu \n\tNS \n\tPropranolol \n\t\u219417% zv\u00FD\u0161en\u00ED Cmax u 4-OH propranololu (topiram\u00E1t 50 mg/12 hod) \n\t9% a 17% zv\u00FD\u0161en\u00ED AUC (40, resp. 80 mg propranololu/12 hod) \n\tSumatriptan (peror\u00E1ln\u00ED a subkut\u00E1nn\u00ED) \n\t\u2194 \n\tNS \n\tPizotifen \n\t\u2194 \n\t\u2194 \n\tDiltiazem \n\t25% sn\u00ED\u017Een\u00ED AUC diltiazemu a 18% sn\u00ED\u017Een\u00ED DEA a \u2194 DEM* \n\t20% zv\u00FD\u0161en\u00ED AUC \n\tVenlafaxin \n\t\u2194 \n\t\u2194 \n\tFlunarizin \n\t (topiram\u00E1t 50 mg/12 hod)b \n\t\u2194 \na Hodnoty v % jsou pr\u016Fm\u011Brn\u00E9 zm\u011Bny Cmax nebo AUC u monoterapie \n\u2194 = \u017E\u00E1dn\u00FD \u00FA\u010Dinek na Cmax a AUC (\u2264 15% zm\u011Bna) p\u016Fvodn\u00EDho l\u00E9\u010Diva \nNS = nebylo studov\u00E1no \n*DEA = des acetyl diltiazem, DEM = N-demethyl diltiazem \nbAUC flunarizinu se zvy\u0161uje o 14 % u subjekt\u016F u\u017E\u00EDvaj\u00EDc\u00EDch flunarizin samostatn\u011B."@cs . . . "26622"^^ . . .